Literature DB >> 25069463

Diabetes: safety and efficacy of albiglutide-results from two trials.

Giuseppe Derosa1, Pamela Maffioli1.   

Abstract

Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control. The recent results from the HARMONY 3 and HARMONY 6 trials suggest that albiglutide is a safe and effective treatment option for patients with type 2 diabetes mellitus.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25069463     DOI： 10.1038/nrendo.2014.126

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Pharmacologic management of type 2 diabetes.

Authors:  William Harper; Maureen Clement; Ronald Goldenberg; Amir Hanna; Andrea Main; Ravi Retnakaran; Diana Sherifali; Vincent Woo; Jean-François Yale
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

2.  Hypoglycemia, its implications in clinical practice, and possible ways to prevent it.

Authors:  Pamela Maffioli; Giuseppe Derosa
Journal:  Curr Med Res Opin       Date:  2014-02-17       Impact factor: 2.580

Review 3.  GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Authors:  Giuseppe Derosa; Pamela Maffioli
Journal:  Curr Clin Pharmacol       Date:  2012-08

Review 4.  Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes.

Authors:  Stuart A Ross
Journal:  Am J Med       Date:  2013-09       Impact factor: 4.965

Review 5.  Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Authors:  Giuseppe Derosa; Pamela Maffioli
Journal:  Diabetes Technol Ther       Date:  2012-02-10       Impact factor: 6.118

6.  Evaluation of risk factors for development of complications in Type II diabetes in Europe.

Authors:  A Liebl; M Mata; E Eschwège
Journal:  Diabetologia       Date:  2002-06-19       Impact factor: 10.122

7.  HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

Authors:  Bo Ahrén; Susan L Johnson; Murray Stewart; Deborah T Cirkel; Fred Yang; Caroline Perry; Mark N Feinglos
Journal:  Diabetes Care       Date:  2014-06-04       Impact factor: 19.112

8.  Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

Authors:  Julio Rosenstock; Vivian A Fonseca; Jorge L Gross; Robert E Ratner; Bo Ahrén; Francis C C Chow; Fred Yang; Diane Miller; Susan L Johnson; Murray W Stewart; Lawrence A Leiter
Journal:  Diabetes Care       Date:  2014-06-04       Impact factor: 19.112

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.

Authors:  A Brett Hauber; Steven Han; Jui-Chen Yang; Ira Gantz; Kaan Tunceli; Juan Marcos Gonzalez; Kimberly Brodovicz; Charles M Alexander; Michael Davies; Kristy Iglay; Qiaoyi Zhang; Larry Radican
Journal:  Patient Prefer Adherence       Date:  2013-09-18       Impact factor: 2.711
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.